Aurora Cannabis initiates production tests with powdery mildew-resistant plants

The Aurora Cannabis Inc., a global leader in medicinal cannabis, announced on Wednesday (15) a significant progress in its research. The company has moved to the industrial-scale production testing phase of genetically resistant cultivars to powdery mildew.

Almost a year after discovering the genetic resistance source named PM2, the tests are taking place at Aurora Ridge's manufacturing unit. The company expects the commercialization of the new strains to happen by 2026.

Scientists from the Aurora Coast research center have conducted multiple rounds of crossings since identifying the marker. The goal is to transfer this resistance to the company's elite lineages without compromising quality.

The aim is to integrate biological defense against the fungus while maintaining cannabinoid and terpene profiles. These characteristics are essential for patients and consumers in markets such as Canada, Europe, Australia, and New Zealand.

Impact of Aurora Cannabis on risk management

Aurora Cannabis' innovation directly addresses one of the industry's most critical points: agricultural risk. According to the Relm Risk Briefing: Cannabis 2026 report, biological contamination is one of the main causes of losses in the sector.

The survey indicates that contaminations, such as mold and mildew, accounted for about 40% of all product recalls in 2024. The technology promises to significantly mitigate these damages.

As an agricultural product, the plant is sensitive to pests that can decimate crops or require expensive environmental controls. The new technology protects plant health intrinsically, reducing operational costs and increasing the safety of the final product.

Scientific validation and Aurora Cannabis' plans

The proprietary technology behind PM2 is the result of a collaboration with researchers from the University of British Columbia. The project is funded by Genome British Columbia and already has patent applications in several countries.

Lana Culley, Vice President of Innovation and International Operations at Aurora Cannabis, highlighted the strategic importance of this phase. "As we move from research to production testing, we are not only validating the science but also shaping the future of cultivation," she stated in a release.

Culley emphasizes that the progress is a crucial step towards commercialization. "This demonstrates how science-based innovation adds significant value to our global portfolio," the executive concluded.

Aurora Cannabis' financial scenario and next steps

The company is experiencing a financial stability moment to support its research initiatives. Recent data indicates that Aurora Cannabis has a market capitalization of approximately US$241.8 million.

Furthermore, the company recorded a revenue growth of 23.89% in the last twelve months, totaling US$263.8 million annually. With a moderate level of debt, the company maintains flexibility to invest in innovation.

The results of the production tests will define the exact launch schedule, but the plan is to make the cultivars available later this year. Investors are awaiting more details in the next results disclosure, scheduled for February 5, 2026.